Image Of Chemical Structure (611e1f43 1442 4cbb B7eb B65de15c6c70 01)
Anastrozole
Product Images NDC 21695-990
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 21695-990). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Of Figure 1 (611e1f43 1442 4cbb B7eb B65de15c6c70 02)
The text describes a figure showing the disease-free survival of patients randomized to receive either anastrozole or tamoxifen monotherapy in the ATAC trial. The figure presents a Kaplan Meier survival curve, with disease-free survival on the y-axis and time (in months) on the x-axis. The curve shows that disease-free survival was higher in patients who received anastrozole compared to tamoxifen. The figure also includes a table of the number of patients at risk at each time point.*
Image Of Figure 2 (611e1f43 1442 4cbb B7eb B65de15c6c70 03)
The figure displays the Disease-free Survival of a hormone receptor-positive subpopulation of patients treated with Anastrozole versus Tamoxifen. The x-axis shows the duration of time (in months) and the y-axis represents the proportion of patients who remain alive and disease-free. It demonstrates that treatment with Anastrozole resulted in better disease-free survival compared to Tamoxifen. The number of patients at risk is also presented below the graph.*
Image Of Figure 3 (611e1f43 1442 4cbb B7eb B65de15c6c70 04)
The figure shows the Kaplan-Meier probability of time to disease progression for patients who were randomized and treated in Trial 0030. The x-axis represents the time to progression in months while the y-axis represents the probability of disease progression. The graph compares the treatment response of the randomized groups who received Nastrozole and Tamoxifen. The figure also includes the number of patients at risk, at each time interval.*
Image Of Figure 4 (611e1f43 1442 4cbb B7eb B65de15c6c70 05)
This text appears to be a figure from a medical trial (Trial 0027) showing the Kaplan-Meier probability of time to progression for randomized patients receiving treatment with an unspecified drug. The horizontal axis represents the time to progression, while the vertical axis shows the probability of progression. The treatment being evaluated in the trial is stated to be "wastrozole". The figure includes a graph of the Kaplan-Meier probability, as well as a table of the number of patients at risk at various time points.*
Anastrozole 1mg (611e1f43 1442 4cbb B7eb B65de15c6c70 06)
This appears to be the description of a medication called Anastrozole, which comes in the form of tablets that contain 1mg of the active ingredient. The tablets are white, round, and have an imprint code "AN;1". The product is manufactured by Natco Pharma Limited, based in Kothur-509 228. A.P. India, and the package ID is RA099030. It is recommended to store the medication at a controlled room temperature between 30°C (59°-86°F) and keep it out of reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
